Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Esophageal Cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2021, there were 609,200 incident cases of esophageal cancer worldwide, and expects that number to increase to 648,100 incident cases by 2030.
- Incidence is higher in males compared to females, and is highest in the Asia region. Merck & Co’s Keytruda, Pinnacle Biologics’ Photofrin, Bristol Myers Squibb’s Opdivo and Yervoy, and Jiangsu Hengrui’s camrelizumab are the only marketed drugs for esophageal cancer. These drugs are administered via the intravenous route.
- The majority of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II, with one drug in the NDA/BLA phase.
- Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs are administered intravenously, with the remainder being oral and intratumoral formulations.
- High-impact upcoming events for drugs in the esophageal cancer space comprise topline Phase II trial results for ADPA2M4CD8, topline Phase III trial results for Imfinzi and tiragolumab, and an expected PDUFA date as well as a CHMP opinion for tislelizumab.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.2%, and the average probability a drug advances from Phase III is 41.7%. Drugs, on average, take 9.9 years from Phase I to approval, compared to 9.8 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 90% of trials in Phase I–II, and only 10% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for esophageal cancer, with 78 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for esophageal cancer, closely followed by Roche and Merck & Co.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Endoscopic therapy
10 Chemotherapy
10 Targeted therapy
10 Immunotherapy
12 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 Tislelizumab for Esophageal Cancer (June 30, 2022)
27 Multiple Drugs for Esophageal Cancer (June 4, 2022)
28 Sintilimab for Esophageal Cancer (September 17, 2021)
29 Toripalimab for Esophageal Cancer (September 16, 2021)
31 Multiple Drugs for Esophageal Cancer (July 28, 2021)
32 Sintilimab for Esophageal Cancer (June 22, 2021)
33 Tislelizumab for Esophageal Cancer (June 4, 2021)
35 Opdivo for Esophageal Cancer (June 3, 2021)
37 Camrelizumab for Esophageal Cancer (May 28, 2021)
39 KEY UPCOMING EVENTS
40 KEY REGULATORY EVENTS
40 Henlius Gets Australian Nod For Trastuzumab
40 BeiGene/Novartis’s Tislelizumab Faces US Delay Over China Inspection Challenges
40 Bristol Builds Out Opdivo Estate In Upper GI Cancers
41 Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs
41 Tislelizumab Among Latest Filings In EU
42 CHMP Recommends Yervoy and Opdivo Combination For Use In Esophageal Cancer
42 Novartis’s Tislelizumab Takes First Step On US Approval Path
43 PROBABILITY OF SUCCESS
44 LICENSING AND ASSET ACQUISITION DEALS
44 Chinese Biotechs Partner Up 18.2-Targeting ADCs Amid Intense Domestic Competition
44 Organon Pays $73m Up Front For Ex-China Rights To Two Biosimilars
45 REVENUE OPPORTUNITY
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
52 BIBLIOGRAPHY
53 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of esophageal cancer, 2021–30
14 Figure 2: Incident cases of esophageal cancer, by gender, 2021
18 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
18 Figure 4: Pipeline drugs for esophageal cancer, by company
19 Figure 5: Pipeline drugs for esophageal cancer, by drug type
19 Figure 6: Pipeline drugs for esophageal cancer, by classification
27 Figure 7: Tislelizumab for Esophageal Cancer (June 30, 2022): Phase III – RATIONALE 306
29 Figure 8: Sintilimab for Esophageal Cancer (September 17, 2021): Phase III – ORIENT-15 (Global)
33 Figure 9: Sintilimab for Esophageal Cancer (June 22, 2021): Phase III – ORIENT-15 (Global)
35 Figure 10: Tislelizumab for Esophageal Cancer (June 4, 2021): Phase III – RATIONALE 302
37 Figure 11: Opdivo for Esophageal Cancer (June 3, 2021): Phase III – CheckMate 648
39 Figure 12: Key upcoming events in esophageal cancer
43 Figure 13: Probability of success in the solid tumors pipeline
46 Figure 14: Clinical trials in esophageal cancer
46 Figure 15: Top 10 drugs for clinical trials in esophageal cancer
47 Figure 16: Top 10 companies for clinical trials in esophageal cancer
47 Figure 17: Trial locations in esophageal cancer
48 Figure 18: Esophageal cancer trials status
49 Figure 19: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of esophageal cancer, 2021–30
16 Table 2: Marketed drugs for esophageal cancer
20 Table 3: Pipeline drugs for esophageal cancer in the US
25 Table 4: Tislelizumab for Esophageal Cancer (June 30, 2022)
27 Table 5: Multiple Drugs for Esophageal Cancer (June 4, 2022)
28 Table 6: Sintilimab for Esophageal Cancer (September 17, 2021)
30 Table 7: Toripalimab for Esophageal Cancer (September 16, 2021)
31 Table 8: Multiple Drugs for Esophageal Cancer (July 28, 2021)
32 Table 9: Sintilimab for Esophageal Cancer (June 22, 2021)
34 Table 10: Tislelizumab for Esophageal Cancer (June 4, 2021)
36 Table 11: Opdivo for Esophageal Cancer (June 3, 2021)
38 Table 12: Camrelizumab for Esophageal Cancer (May 28, 2021)
45 Table 13: Historical global sales, by drug ($m), 2017–21
45 Table 14: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Duchenne Muscular Dystrophy (DMD) 
Sign up to the